Comparative Pharmacology
Head-to-head clinical analysis: REGLAN versus REGLAN ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REGLAN versus REGLAN ODT.
REGLAN vs REGLAN ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metoclopramide is a dopamine D2 receptor antagonist and a serotonin 5-HT4 receptor agonist. It enhances gastrointestinal motility by increasing acetylcholine release from myenteric nerve terminals and sensitizes tissues to acetylcholine. It also has central antiemetic effects via chemoreceptor trigger zone blockade.
Metoclopramide, the active ingredient, is a dopamine D2 receptor antagonist and also sensitizes tissues to acetylcholine by facilitating cholinergic transmission in the myenteric plexus. It enhances upper gastrointestinal motility without stimulating gastric secretions.
10 mg orally 4 times daily 30 minutes before meals and at bedtime; or 5-10 mg intramuscularly or intravenously every 4-6 hours as needed; maximum 30 mg/day intravenous for diabetic gastroparesis.
10 mg orally 4 times daily (30 minutes before meals and at bedtime)
None Documented
None Documented
Terminal elimination half-life is 4 to 6 hours in patients with normal renal function. In patients with creatinine clearance <40 mL/min, half-life is prolonged significantly, requiring dose adjustment.
Terminal elimination half-life is 5-6 hours in patients with normal renal function. Prolonged in renal impairment (up to 15 hours in severe cases).
Approximately 85% of an oral dose is excreted in urine (as unchanged drug and conjugates) and about 5-10% in feces via biliary elimination.
Renal (85% as unchanged drug and conjugates, 5% as unchanged metoclopramide), fecal (10%).
Category C
Category C
Dopamine Antagonist Antiemetic
Dopamine Antagonist Antiemetic